Published in Cancer Weekly, January 29th, 2002
Under terms of the agreement, DGI becomes an equal research partner for in vitro and in vivo testing. Novo Nordisk will obtain exclusive rights to IGF antagonists, while DGI will maintain rights to IGF agonists that are discovered as a result of the collaboration. Financial terms of the agreement were not disclosed.
IGF, or insulin-like growth factor, is a natural growth-promoting entity, the blockage of whose action has attracted attention as a potential...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.